Centro Nacional De Investigaciones Oncologicas (cnio)

Fundacion Centro Nacional De Investigaciones Oncologicas Carlos III

Fundacion Del Sector Publico Estatal Centro Nacional De Investigaciones Oncologicas Carlos III

Joaquin Pastor Fernández

Sonia Martínez González

Jose Ignacio Martín Hernando

Antonio Rodríguez Hergueta

Rosario Concepción Riesco Fagundo

Carmen Blanco Aparicio

Julen Oyarzabal Santamarina

Rosa Maria Álvarez Escobar

Ana Belén García García

David Álvaro Cebrián Muñoz

Francisco Javier Ramos Lima

Cristina Ana Gómez De La Oliva

Sonia Martínez Gonzalez

Guido Kurz

Carmen Blanco Aparicío

James R Bischoff

Ana Ortega Molina

Manuel Serrano Marugan

María Isabel Albarrán Santiño

Esther González Cantalapiedra

Elena Hernández Encinas

Ana Belén GARCÍA GARCÍA

David ÁLvaro CEBRIÁN MUÑOZ

Rosa María ÁLvarez Escobar

José Ignacio MARTÍN Hernando

Rosa María Alvarez Escobar

Antonio Cebriá Gómez

The first aspect of the invention relates to a phosphoinositide 3-kinase inhibitor for use in the treatment or prevention of a disease or condition associated with the expression of peroxisome proliferator-activated receptor gamma coactivator 1-&#x3b1; (Pgd1&#x3b1;) and/or uncoupling protein 1 (Thermogenin/Ucp1) in brown adipocytes. The disease or condition may be positive energy imbalance-associated, for example, obesity, an obesity-associated disease or condition, steatosis and biological aging (performance aging). Another aspect of the invention provides the use of a phosphoinositide 3-kinase inhibitor for promoting weight loss in an individual.

Use of P13K Inhibitors for the Treatment of Obesity, Steatosis and ageing

There is provided compounds of formula I, wherein R1, R, R, R, X, Y, Z, Rand ring A/B have meanings given in the description, and pharmaceutically-acceptable esters, amides, solvates or salts thereof, which compounds are useful in the treatment of diseases in which inhibition of a protein or lipid kinase (e.g. PI3-K, particularly class I PI3K, PIM family kinase and/or mTOR) is desired and/or required, and particularly in the treatment of cancer. The invention also relates to combinations containing such compounds. 

Macrocyclic compounds as protein kinase inhibitors

There is provided compounds of formula (I), wherein A, A, A, A, B, B, B, B, B, B, B, Band Rhave meanings given in the description, and pharmaceutically-acceptable esters, amides, solvates or salts thereof, which compounds are useful in the treatment of diseases in which inhibition of a protein or lipid kinase (e.g. a PI3-K and/or mTOR) is desired and/or required, and particularly in the treatment of cancer or a proliferative disease. 

Inhibitors of PI3 kinase

There is provided compounds of formula (I): wherein R, Rand Rhave meanings given in the description, and pharmaceutically-acceptable esters, amides, solvates or salts thereof, which compounds are useful in the treatment of diseases in which inhibition of a protein or lipid kinase (e.g. PI3-K, particularly class I PI3K) is desired and/or required, and particularly in the treatment of cancer. 

Imidazo [2, 1-B] [1, 3, 4] thiadiazole derivatives

There is provided compounds of formula (I), wherein R, R, R, Rand Rhave meanings given in the description, and pharmaceutically-acceptable esters, amides, solvates or salts thereof, which compounds are useful in the treatment of diseases in which inhibition of a protein or lipid kinase (e.g. a PI3-K and/or mTOR) is desired and/or required, and particularly in the treatment of cancer or a proliferative disease. 

Imidazopyrazines for use as kinase inhibitors

Growing community of inventors

Madrid, Spain

Joaquin Pastor Fernández